What are the timelines for development and commercialisation?
Both Mesoblast and its sister company, Angioblast Systems Inc in the United States, are very well positioned to continue rapid product commercialisation for both orthopaedic and cardiovascular applications, respectively, based on the shared adult stem cell technology platform. Mesoblast has made tremendous progress in the two years since its December 2004 public listing and has accomplished many of its objectives well ahead of schedule. The ensuing six to 12 months should be equally exciting as the company commences US Food and Drug Administration (FDA) clinical trials and advances new applications. Major recent milestones accomplished by Mesoblast include: A successful Investigational New Drug (IND) submission to the FDA to commence a Phase 2 Clinical Trial for spinal fusion; Positive results from clinical and pre-clinical trials; Validation of its high-margin business model to use off-the-shelf adult stem cells in unrelated, or allogeneic, recipients Granted a key patent in the US .
